L
Lynn L. Silver
Researcher at Merck & Co.
Publications - 75
Citations - 9617
Lynn L. Silver is an academic researcher from Merck & Co.. The author has contributed to research in topics: Plasmid & Antibacterial agent. The author has an hindex of 34, co-authored 72 publications receiving 7472 citations. Previous affiliations of Lynn L. Silver include DuPont & Brandeis University.
Papers
More filters
Journal ArticleDOI
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli,Elena Carrara,Alessia Savoldi,Stéphan Juergen Harbarth,Marc Mendelson,Dominique L Monnet,Céline Pulcini,Gunnar Kahlmeter,Jan Kluytmans,Yehuda Carmeli,Marc Ouellette,Kevin Outterson,Jean B. Patel,Marco Cavaleri,Edward Cox,Christopher R. Houchens,M Lindsay Grayson,Paul Hansen,Nalini Singh,Ursula Theuretzbacher,Nicola Magrini,Aaron O. Aboderin,Seif Al-Abri,Nordiah Awang Jalil,Nur Benzonana,Sanjay Bhattacharya,Adrian Brink,Francesco Robert Burkert,Otto Cars,Giuseppe Cornaglia,Oliver J. Dyar,Alexander W. Friedrich,Ana Cristina Gales,Sumanth Gandra,Christian G. Giske,Debra A. Goff,Herman Goossens,Thomas Gottlieb,Manuel Guzman Blanco,Waleria Hryniewicz,Deepthi Kattula,Timothy Jinks,Souha S. Kanj,Lawrence Kerr,Marie-Paule Kieny,Yang Soo Kim,Roman S. Kozlov,Jaime Labarca,Ramanan Laxminarayan,Karin Leder,Leonard Leibovici,Gabriel Levy-Hara,Jasper Littman,Surbhi Malhotra-Kumar,Vikas Manchanda,Lorenzo Moja,Babacar Ndoye,Angelo Pan,David L. Paterson,Mical Paul,Haibo Qiu,Pilar Ramon-Pardo,Jesús Rodríguez-Baño,Maurizio Sanguinetti,Sharmila Sengupta,Mike Sharland,Massinissa Si-Mehand,Lynn L. Silver,Wonkeung Song,Martin Steinbakk,Jens Thomsen,Guy E. Thwaites,Jos W. M. van der Meer,Nguyen Van Kinh,Silvio Vega,Maria Virginia Villegas,Agnes Wechsler-Fördös,Heiman F. L. Wertheim,Evelyn Wesangula,Neil Woodford,Fidan O Yilmaz,Anna Zorzet +81 more
TL;DR: Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria, and include antibiotic-resistant bacteria responsible for community-acquired infections.
Journal ArticleDOI
Challenges of Antibacterial Discovery
TL;DR: The purpose of this review is to underscore and illustrate those scientific problems unique to the discovery and optimization of novel antibacterial agents that have adversely affected the output of the effort.
Journal ArticleDOI
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Jun Wang,Stephen M. Soisson,Katherine Young,Wesley L. Shoop,Wesley L. Shoop,Srinivas Kodali,Andrew Galgoci,Ronald E. Painter,Gopalakrishnan Parthasarathy,Yui S. Tang,Richard D. Cummings,Sookhee Ha,Karen Dorso,Mary Motyl,Hiranthi Jayasuriya,John G. Ondeyka,Kithsiri Herath,Chaowei Zhang,Lorraine D. Hernandez,John J. Allocco,Angela Basilio,José R. Tormo,Olga Genilloud,Francisca Vicente,Fernando Pelaez,Lawrence F. Colwell,Sang Ho Lee,B.F. Michael,Thomas J. Felcetto,Charles Gill,Lynn L. Silver,Lynn L. Silver,Jeffery D. Hermes,Ken Bartizal,John F. Barrett,Dennis M. Schmatz,Joseph W. Becker,Doris F. Cully,Sheo B. Singh +38 more
TL;DR: Platensimycin demonstrates strong, broad-spectrum Gram-positive antibacterial activity by selectively inhibiting cellular lipid biosynthesis through the selective targeting of β-ketoacyl-(acyl-carrier-protein (ACP) in the synthetic pathway of fatty acids.
Journal ArticleDOI
Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center
Neil Woodford,Philip M. Tierno,Katherine Young,Luke Tysall,Marie-France I. Palepou,Elaina Ward,Ronald E. Painter,Deborah F. Suber,D L Shungu,Lynn L. Silver,Kenneth Inglima,John Kornblum,David M. Livermore +12 more
TL;DR: This is the third KPC carbapenem-hydrolyzing β-lactamase variant to have been reported in members of the Enterobacteriaceae, with others reported from the East Coast of the United States.
Journal ArticleDOI
Antibacterial agents that inhibit lipid A biosynthesis
H. Russell Onishi,Barbara A. Pelak,Lynn S. Gerckens,Lynn L. Silver,Frederick M. Kahan,Meng-Hsin Chen,Arthur A. Patchett,Susan M. Galloway,Sheryl A. Hyland,Matt S. Anderson,Christian R. H. Raetz +10 more
TL;DR: Synthetic antibacterials were identified that inhibit the second enzyme (a unique deacetylase) of lipid A biosynthesis that constitutes the outer monolayer of the outer membrane of Gram-negative bacteria and is essential for bacterial growth.